Doctors primarily select patients for Zytiga monotherapy based on their overall health and the specifics of their prostate cancer. Patients with good general health and a manageable symptom burden are better candidates.
Factors favoring monotherapy include: Low risk of severe side effects from prednisone, such as diabetes or osteoporosis. Patients with a history of these conditions, or other contraindications to corticosteroids, may benefit from Zytiga alone.
However, it’s crucial to weigh potential benefits against risks. While prednisone enhances Zytiga’s efficacy, its omission might lead to a less robust anti-cancer effect. Therefore, careful monitoring of disease progression is absolutely necessary.
Close monitoring includes: Regular PSA tests and imaging studies to track tumor response. Patients should report any new or worsening symptoms promptly to their healthcare provider. Frequent blood tests assess for potential side effects, such as diarrhea, fatigue, or high blood pressure. This allows for early intervention and adjustment of treatment.
Alternatives should be discussed: If monotherapy proves insufficient, the physician might recommend adding prednisone or exploring other treatment options. The decision always rests on a patient’s unique circumstances and preferences, guided by the latest clinical evidence.
